BCNLF BIOCANCELL LTD

Anchiano Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference

Anchiano Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, being held September 4-6, 2018 at the St. Regis Hotel in New York City.

Anchiano Therapeutics Presentation Details
Date:Thursday, September 6
Time: 10:50am Eastern Time
Location:The St. Regis New York, Library (2nd Floor)

The presentation will be webcast live and remain available for 90 days following the presentation. To view the webcast, please visit . To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time.

About Anchiano Therapeutics

Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. The Company’s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. For additional information on inodiftagene vixteplasmid or upcoming clinical trials please go to .  

Company Contact:

Frank Haluska, M.D., Ph.D.

President and Chief Executive Officer

Investor Contact:

Ashley R. Robinson

Managing Director

LifeSci Advisors, LLC

617-535-7742

EN
05/09/2018

Underlying

BCNLFBIOCANCELL LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOCANCELL LTD

 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Closing of $30.5 Million Initial Publ...

Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS resulting in gross proceeds of $30.5 million. The ADSs began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019. The underwriters have been granted a 30-day option ...

February 14, 2019 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Publi...

Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering CAMBRIDGE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has priced its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS, less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019, and the offering is expected to clos...

February 12, 2019 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Filing of F-1 Registration Statement f...

Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for the proposed initial public offering in the United States of American Depositary Shares (“ADSs”) representing ordinary shares of Anchiano Therapeutics. The numbe...

January 7, 2019 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study ...

Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the initiation of Codex, the Company's pivotal Phase 2 study of inodiftagene vixteplasmid (BC-819), a first-in-class gene therapy for patients with non-muscle-invasive bladder cancer (NMIBC). The study will enroll 140 patients wit...

December 18, 2018 1 EN
 PRESS RELEASE
Free
BCNLF BIOCANCELL LTD

Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as N...

Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company’s new Chief Medical Officer. Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies. “We are thrilled to have David, a skilled medical lead and ac...

November 26, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch